| Progress of mechanisms of glucagon-like peptide-1 in ameliorating nonalcoholic fatty liver disease |
| Received:September 24, 2019 Revised:May 07, 2020 Click here to download the full text |
| Citation of this paper:LI Wen-cun,YUAN Li.Progress of mechanisms of glucagon-like peptide-1 in ameliorating nonalcoholic fatty liver disease[J].Chinese Journal of Clinical Medicine,2020,27(5):861-865 |
| Hits: 1550 |
| Download times: 480 |
| Author Name | Affiliation | E-mail | | LI Wen-cun | Department of Endocrinology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei, China | | | YUAN Li | Department of Endocrinology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei, China | yuanli18cn@163.com |
|
| Abstract:Nonalcoholic fatty liver disease (NAFLD) is closely associated with obesity, insulin resistance, type 2 diabetes mellitus, and lipid disorders. With the growing incidence of obesity and diabetes, NAFLD has become the most common chronic liver disease worldwide. At present, the treatment of NAFLD is mainly limited to lifestyle intervention, reduction of weight, and use of lipid-lowering drugs, but there is no specific drug for NAFLD. Glucagon-like peptide-1 (GLP-1) has been approved for diabetes and obesity, and numerous clinical and preclinical studies have shown that GLP-1 could alleviate NAFLD by multiple mechanisms. In this paper, the mechanisms of GLP-1 in improving NAFLD are summarized as follows. |
| keywords:glucagon-like peptide-1 nonalcoholic fatty liver disease molecular mechanism |
| HTML View Full Text View/Add Comment Download reader |
|
|
|